DK3199553T3 - Fremgangsmåder og midler til diagnosticering og behandling af hepatocellulært carcinom - Google Patents
Fremgangsmåder og midler til diagnosticering og behandling af hepatocellulært carcinom Download PDFInfo
- Publication number
- DK3199553T3 DK3199553T3 DK17158755.3T DK17158755T DK3199553T3 DK 3199553 T3 DK3199553 T3 DK 3199553T3 DK 17158755 T DK17158755 T DK 17158755T DK 3199553 T3 DK3199553 T3 DK 3199553T3
- Authority
- DK
- Denmark
- Prior art keywords
- diagnostication
- agents
- treatment
- methods
- carcinom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19765008P | 2008-10-29 | 2008-10-29 | |
| EP09792374.2A EP2346904B1 (en) | 2008-10-29 | 2009-09-09 | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3199553T3 true DK3199553T3 (da) | 2019-07-22 |
Family
ID=41395384
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17158755.3T DK3199553T3 (da) | 2008-10-29 | 2009-09-09 | Fremgangsmåder og midler til diagnosticering og behandling af hepatocellulært carcinom |
| DK09792374.2T DK2346904T3 (da) | 2008-10-29 | 2009-09-09 | Fremgangsmåder og midler til diagnosen og behandling af hepatocellular carcinom |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09792374.2T DK2346904T3 (da) | 2008-10-29 | 2009-09-09 | Fremgangsmåder og midler til diagnosen og behandling af hepatocellular carcinom |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8821880B2 (da) |
| EP (2) | EP2346904B1 (da) |
| DK (2) | DK3199553T3 (da) |
| ES (2) | ES2732504T3 (da) |
| TW (2) | TWI466895B (da) |
| WO (1) | WO2010051105A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009226152A1 (en) | 2008-03-19 | 2009-09-24 | China Synthetic Rubber Corporation | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
| AU2009234444A1 (en) * | 2008-04-11 | 2009-10-15 | China Synthetic Rubber Corporation | Methods, agents and kits for the detection of cancer |
| EP2346904B1 (en) | 2008-10-29 | 2017-04-12 | China Synthetic Rubber Corporation | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
| WO2012000994A1 (en) * | 2010-06-29 | 2012-01-05 | C.N.R.S. | Llt-1 antibodies with new functional properties |
| US9493552B2 (en) | 2013-11-15 | 2016-11-15 | China Synthetic Rubber Corporation | Therapeutic biologic for treatment of hepatocellular carcinoma |
| CN108997497B (zh) * | 2018-03-30 | 2022-02-25 | 华兰基因工程有限公司 | 特异结合人质膜膜泡关联蛋白pv-1的单克隆抗体及其制备方法与应用 |
| JP2022513338A (ja) * | 2018-10-03 | 2022-02-07 | ネペンザ・バイオサイエンシズ・エルエルシー | 抗ｃｄ７９抗体およびその使用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172124A (en) | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
| IT1203672B (it) | 1982-05-12 | 1989-02-15 | Harvard College | Proteina ibrida comprendente frammenti proteici collegati da legami peptidici e relativo gene di fusione composizione contenente tale proteina |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| JP3771253B2 (ja) | 1988-09-02 | 2006-04-26 | ダイアックス コープ． | 新規な結合タンパク質の生成と選択 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| WO1991003162A1 (en) | 1989-08-31 | 1991-03-21 | City Of Hope | Chimeric dna-rna catalytic sequences |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JP3257675B2 (ja) | 1990-10-12 | 2002-02-18 | マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． | 修飾リボザイム |
| EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ES2330052T3 (es) | 1991-03-01 | 2009-12-03 | Dyax Corporation | Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas. |
| US5440021A (en) | 1991-03-29 | 1995-08-08 | Chuntharapai; Anan | Antibodies to human IL-8 type B receptor |
| EP0580737B1 (en) | 1991-04-10 | 2004-06-16 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE4216134A1 (de) | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| US5496698A (en) | 1992-08-26 | 1996-03-05 | Ribozyme Pharmaceuticals, Inc. | Method of isolating ribozyme targets |
| US5525468A (en) | 1992-05-14 | 1996-06-11 | Ribozyme Pharmaceuticals, Inc. | Assay for Ribozyme target site |
| US5646020A (en) | 1992-05-14 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | Hammerhead ribozymes for preferred targets |
| US5891684A (en) | 1992-10-15 | 1999-04-06 | Ribozyme Pharmaceuticals, Inc. | Base-modified enzymatic nucleic acid |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| US5631359A (en) | 1994-10-11 | 1997-05-20 | Ribozyme Pharmaceuticals, Inc. | Hairpin ribozymes |
| US20040067490A1 (en) | 2001-09-07 | 2004-04-08 | Mei Zhong | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| AU1181802A (en) | 2000-09-27 | 2002-04-08 | Curagen Corp | Novel proteins and nucleic acids encoding same |
| DE10136273A1 (de) | 2001-07-25 | 2003-02-13 | Sabine Debuschewitz | Molekulare Marker beim hepatozellulären Karzinom |
| NZ573831A (en) | 2001-09-18 | 2010-07-30 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193 |
| DK1866414T3 (da) | 2005-03-31 | 2012-04-23 | Calando Pharmaceuticals Inc | Inhibitorer af ribonukleotidreduktase-underenhed 2 og anvendelser deraf. |
| WO2006110593A2 (en) | 2005-04-07 | 2006-10-19 | Macrogenics, Inc. | Biological targets for the diagnosis, treatment and prevention of cancer |
| US20080233117A1 (en) | 2007-01-22 | 2008-09-25 | Mayo Foundation For Medical Education And Research | Reducing tumor growth |
| AU2009226152A1 (en) | 2008-03-19 | 2009-09-24 | China Synthetic Rubber Corporation | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
| AU2009234444A1 (en) | 2008-04-11 | 2009-10-15 | China Synthetic Rubber Corporation | Methods, agents and kits for the detection of cancer |
| EP2346904B1 (en) | 2008-10-29 | 2017-04-12 | China Synthetic Rubber Corporation | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
-
2009
- 2009-09-09 EP EP09792374.2A patent/EP2346904B1/en active Active
- 2009-09-09 DK DK17158755.3T patent/DK3199553T3/da active
- 2009-09-09 DK DK09792374.2T patent/DK2346904T3/da active
- 2009-09-09 EP EP17158755.3A patent/EP3199553B1/en active Active
- 2009-09-09 US US13/126,734 patent/US8821880B2/en active Active
- 2009-09-09 ES ES17158755T patent/ES2732504T3/es active Active
- 2009-09-09 ES ES09792374.2T patent/ES2631507T3/es active Active
- 2009-09-09 WO PCT/US2009/056382 patent/WO2010051105A1/en active Application Filing
- 2009-09-18 TW TW98131450A patent/TWI466895B/zh active
- 2009-09-18 TW TW103140971A patent/TWI542687B/zh active
-
2014
- 2014-07-21 US US14/336,441 patent/US9394359B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2732504T3 (es) | 2019-11-22 |
| TWI466895B (zh) | 2015-01-01 |
| US20110262349A1 (en) | 2011-10-27 |
| EP3199553B1 (en) | 2019-04-24 |
| US20150017171A1 (en) | 2015-01-15 |
| TW201017169A (en) | 2010-05-01 |
| TWI542687B (zh) | 2016-07-21 |
| US9394359B2 (en) | 2016-07-19 |
| EP2346904A1 (en) | 2011-07-27 |
| WO2010051105A1 (en) | 2010-05-06 |
| EP2346904B1 (en) | 2017-04-12 |
| EP3199553A1 (en) | 2017-08-02 |
| DK2346904T3 (da) | 2017-06-12 |
| US8821880B2 (en) | 2014-09-02 |
| ES2631507T3 (es) | 2017-08-31 |
| TW201510218A (zh) | 2015-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3150240T3 (da) | Systemer og fremgangsmåder til fremføring af terapeutiske midler | |
| DK2252342T3 (da) | Indretninger og fremgangsmåder til behandling af skadet væv | |
| DK2350416T4 (da) | Multipel rude med mindst én antirefleksbehandling og anvendelse af antirefleksbehandling i multipel rude | |
| DK2340042T3 (da) | Fremgangsmåder og præparater til behandling af cancer | |
| DK2475372T4 (da) | Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse | |
| DK2114447T3 (da) | Forebyggelse og behandling af subkliniks pcvd | |
| DK2414507T3 (da) | Mutanter af aktiveringsinduceret cytidin-deaminase (aid) og til anvendelsesfremgangsmåder | |
| DK2894165T3 (da) | Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser | |
| DK2114531T3 (da) | Punktpropper og fremgangsmåder til indgivelse af terapeutiske midler | |
| DK2445489T3 (da) | Sammensætninger til behandling af narkotikamisbrug og forbedring af misbrugsrelateret adfærd | |
| DK2350096T3 (da) | Fremgangsmåder til behandling af hepatisk encephalopati | |
| DK2322221T3 (da) | Farmaceutisk sammensætning til behandling og forebyggelse af cancer | |
| DK2356093T3 (da) | Carbazolforbindelser og terapeutiske anvendelser af forbindelserne | |
| DK2191831T3 (da) | Modificering af pirfenidon-behandling for patienter med atypisk leverfunktion | |
| DK2632954T4 (da) | Midler og fremgangsmåder til behandling af dlbcl | |
| BRPI0907109A2 (pt) | lenço dental e método | |
| DK2398902T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af cancer | |
| DK2253724T3 (da) | Fremgangsmåde til behandling af sfæroidt grafitjern | |
| DK3216457T3 (da) | Forbindelser og fremgangsmåder til forebyggelsen eller behandlingen af restenose | |
| DK2319036T3 (da) | Indretning og fremgangsmåde til frembringelse af eksplosioner | |
| DK2297106T3 (da) | Phenoxypyridinylamidderivater og deres anvendelse til behandling af pde4-medierede sygdomstilstande | |
| DK2222314T3 (da) | Anvendelser og midler til opnåelse af bronchorelaxation | |
| DK2231678T3 (da) | Fremgangsmåde til selektiv deprotonisering og funktionalisering af 1-fluor-2-substituerede 3-chlorbenzener | |
| DK2235002T3 (da) | 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer | |
| DK3199553T3 (da) | Fremgangsmåder og midler til diagnosticering og behandling af hepatocellulært carcinom |